checkAd

    Neues Gen-Patentgesetz positiv für Celera ? - 500 Beiträge pro Seite

    eröffnet am 06.01.01 10:11:46 von
    neuester Beitrag 19.01.01 09:40:33 von
    Beiträge: 12
    ID: 324.714
    Aufrufe heute: 0
    Gesamt: 797
    Aktive User: 0


     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 06.01.01 10:11:46
      Beitrag Nr. 1 ()
      Die USA haben ein neues Gen-Patentgesetz verabschiedet:

      U.S. issues new patent guidelines on genes
      By Maggie Fox, Health and Science Correspondent

      WASHINGTON, Jan 5 (Reuters) - The U.S. Patent and Trademark Office released new guidelines on Friday meant to clarify the controversial and ambiguous business of patenting genes.

      The rules were intended to help end what has become an acrimonious debate on patenting genes, a multimillion-dollar business for many companies.

      They put to rest any question about whether genes can be patented -- making clear that companies may do so, though they may not patent mere genetic sequences or pieces of genes.

      "But when the inventor also discloses how to use the purified gene isolated from its natural state, the application satisfies the `utility` requirement," the new guidelines read.

      The guidelines were barely changed from interim rules issued a year ago, the Patent Office said. They leave biotech companies such as Rockville, Maryland-based Celera Genomics <CRA.N> and Human Genome Sciences Inc. <HGSI.O> free to continue patenting genes they are racing to identify.

      Arguments against the whole idea of patenting genes -- based on the premise that genes are a part of nature and not an invention -- were soundly rejected by the Patent Office.

      "Several comments state that a gene is not a new composition of matter because it exists in nature, and/or that an inventor who isolates a gene does not actually invent or discover a patentable composition because the gene exists in nature," said the guidelines, posted on the Internet at http://www.access.gpo.gov/su_docs/aces/fr-cont.html.

      "Another comment expressed concern that a person whose body includes a patented gene could be guilty of patent infringement."

      In response after response to more than a dozen such comments, the Patent Office said the law clearly allowed for genes to be patented, so long as those genes have been "cloned" or reproduced in the laboratory and their function is defined.

      "An excised gene is eligible for a patent as a composition of matter or as an article of manufacture because that DNA molecule does not occur in that isolated form in nature," it said. "Synthetic DNA preparations are eligible for patents because their purified state is different from the naturally occurring compound."

      The Patent Office said the practice of patenting bits and pieces of nature was not new. "For example, Louis Pasteur received U.S. Patent 141,072 in 1873, claiming `yeast, free from organic germs of disease, as an article of manufacture`," it said. "Another example is an early patent for adrenaline."

      The entire sequence of a gene does not have to be published to get it patented. "Describing the complete chemical structure, i.e., the DNA sequence, is one method of describing a DNA molecule but it is not the only method," it said.

      Companies have asked for patents on tens of thousands of human genes. Human Genome Sciences says it holds 159 patents on full-length genes, for example, and has filed applications on more than 16,000 genes.

      (( -- Washington newsroom 202 898 8300, fax 202 898 8383, e-mail washington.bureau.newsroom@reuters.com))

      REUTERS

      Wie wird sich dies auf die og. Unternehmen auswirken ?
      Was denkt Ihr ?

      Gruß
      radex
      Avatar
      schrieb am 06.01.01 10:14:08
      Beitrag Nr. 2 ()
      Weiteres zu og. Thema:

      UPDATE 1-U.S. issues new patent guidelines on genes
      (Writes through with comments, reaction) By Maggie Fox, Health and Science Correspondent

      WASHINGTON, Jan 5 (Reuters) - New guidelines aimed at stopping companies from making frivolous attempts to patent genes before they really have any use for them were issued by the U.S. Patent and Trademark Office on Friday.

      The rules were intended to help end what has become an acrimonious debate on patenting genes, a multimillion dollar business for many companies.

      They put to rest any question about whether genes can be patented at all -- making it clear that companies may indeed patent genes or even pieces of genes, though they may not patent mere genetic sequences.

      "It`s raised the bar," said Brigid Quinn, a spokeswoman for the patent office, told Reuters. "You can patent a gene but you have to patent the gene with a use."

      The guidelines are barely changed from interim rules issued a year ago, the patent office said. They leave biotech companies such as Rockville, Maryland-based Celera Genomics <CRA.N> and Human Genome Sciences Inc. <HGSI.O> free to continue patenting genes they are racing to identify.

      Quinn said the new guidelines added another hurdle before anyone can get a patent on a range of technologies, but biotechnology is the industry most clearly affected.

      To show "utility," an applicant had to prove that the discovery had credible and specific uses. Now they must also show that use is "substantial," Quinn said.

      "An example would be that genes express proteins and any protein could be an additive to dog food or shampoo," she said. "However, it would not meet the requirement of a substantial utility because in the real world people would not spend the enormous amounts of money to isolate the gene to put into dog food and shampoo."

      Paul Gilman, a senior executive at Celera, said this would have the effect of stopping companies from making up a possible use for a newly discovered gene and patenting it before they find out how it really works. THEY DON`T WANT YOU TO GUESS A GENE`S USE

      "They don`t want you to sort of guess and say this patent covers everything in the universe. That defeats the purpose of a patent," said Gilman, adding that Celera was pleased with the guidelines.

      So, while Salt Lake City-based Myriad Genetics Inc. <MYGN.O> owns nine patents on the BRCA1 and BRCA2 genes associated with breast cancer, anyone who discovered a whole new role or use for those genes could apply for a separate patent.

      "In the real world they usually cross-license, so each can use the other`s application," Quinn said.

      Arguments against the whole idea of patenting genes -- based on the premise that genes are a part of nature and not an invention -- were soundly rejected by the patent office.

      "Several comments state that a gene is not a new composition of matter because it exists in nature," according to the guidelines, posted on the Internet at http://www.access.gpo.gov/su_docs/aces/fr-cont.html.

      "Another comment expressed concern that a person whose body includes a patented gene could be guilty of patent infringement."

      But, in response after response to more than a dozen such comments, the patent office said the law clearly allowed for genes to be patented -- so long as those genes have been "cloned" or reproduced in the laboratory and their function is defined in some way.

      The patent office also said the entire sequence of a gene does not have to be published for someone to patent it. "Describing the complete chemical structure, i.e., the DNA sequence, is one method of describing a DNA molecule but it is not the only method," it said.

      Companies have asked for patents on tens of thousands of human genes. Human Genome Sciences says it holds 159 patents on full-length genes, for example, and has filed applications on more than 16,000 others. Celera has applied for several thousand patents but has yet to have one granted.

      (( -- Washington newsroom 202 898 8300, fax 202 898 8383, e-mail washington.bureau.newsroom@reuters.com))

      REUTERS

      Rtr 16:52 01-05-01

      Copyright 2001, Reuters News Service. All rights reserved. Replication or redistribution of Reuter`s content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.


      Vielleicht kann ja ein "Engländer" die Berichte übersetzen. Ich bin da nicht so besonders.

      Eure Meinung ?

      Gruß
      radex
      Avatar
      schrieb am 06.01.01 18:15:39
      Beitrag Nr. 3 ()
      Hallo Leute,

      Eure Meinung ?
      Avatar
      schrieb am 08.01.01 16:34:05
      Beitrag Nr. 4 ()
      Celera=strong buy
      Avatar
      schrieb am 08.01.01 18:01:14
      Beitrag Nr. 5 ()
      JA,strong buy* heute ja nur 5% im Minus.

      Trading Spotlight

      Anzeige
      Rallye II. – Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…mehr zur Aktie »
      Avatar
      schrieb am 13.01.01 18:12:24
      Beitrag Nr. 6 ()
      Celera hat seit Montag um 30% zugelegt.
      Da scheint doch was im Busch zu sein ?

      Gruß
      radex
      Avatar
      schrieb am 13.01.01 20:16:27
      Beitrag Nr. 7 ()
      Hi Radex,

      "ich bin schon seit 35,3 E massiv
      im Busch"!!!

      Der Startschuß ist gegeben, ich denke auch,
      daß da noch einiges kommt.
      Gestern im Amiland wieder +10 %.

      ...so long Mac Lood
      Avatar
      schrieb am 15.01.01 15:52:52
      Beitrag Nr. 8 ()
      15.01.2001
      Celera Genomics billig
      Global Biotech Investing


      Die Experten von Global Biotech Investing halten ein Investment in Celera Genomics (WKN 920954) für aussichtsreich.

      Das amerikanische Biotech-Unternehmen verfüge über einen Barbestand von 2,2 Mrd. USD habe aber zur Zeit nur einen Börsenwert von 1,8 Mrd. USD. Das würde bedeuten, dass man derzeit jeden Dollar zu 70 Cents kaufen könne und das komplette Unternehmen noch gratis dazu bekomme. Diese außergewöhnliche Situation werde allerdings auf Dauer keinen Bestand haben. Daher raten die Experten von Global Biotech Investing auf dem aktuellen Niveau zum Kauf.





      ...und billig, da stehste doch drauf!
      Avatar
      schrieb am 15.01.01 20:36:37
      Beitrag Nr. 9 ()
      Bin zwar kein Engländer, kann aber das wesentliche aus den obigen Berichten rauslesen.

      Bislang konnte ein einmal entdecktes Gen angemeldet und patentiert werden, egal wofür es stand.
      Jetzt wurde hier ein Riegel vorgeschoben in der Form, daß ein Gen nur patentiert werden kann, wenn man nachweisen kann, wo der Nutzen liegt. Celera und HGS wurden nur als Beispiele erwähnt, daß diese Firmen auf jedes von ihnen einmal entdeckte Gen und Teile des Gens ein Patent angemeldet hat.

      Davon abgesehen, ist Celera z,Zt, wirklich ein Schnäppchen.
      Hoffe, konnte Euch helfen.

      Gruss, Tici
      Avatar
      schrieb am 18.01.01 19:19:08
      Beitrag Nr. 10 ()
      Heute kommen die Zahlen Q-IV von Celera.
      Weis schon jemand was.
      Wann ist die Veröffentlichung?

      Im Augenblick ist Celera 5% im Plus.
      Wird auch rege gehandelt.


      Gruß
      radex
      Avatar
      schrieb am 18.01.01 23:28:45
      Beitrag Nr. 11 ()
      Also ich meine die Zahlen kommen 25.01.2001!


      Gruss Franka
      Avatar
      schrieb am 19.01.01 09:40:33
      Beitrag Nr. 12 ()
      Stimmt, Du hast recht.

      Ich bin auf die Tagesveröffentlichung von Yahoo und Comdirect reingefallen.

      In Nasdaq.com steht der 25.1. vor Börseneröffnung.

      Gruß

      PS.: Gestern nachbörslich 44,5$ !


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.
      Neues Gen-Patentgesetz positiv für Celera ?